Third phase of human trials for Indian vaccines to begin in multiple cities soon

The constant rat race to launch a coronavirus vaccine has immeasurably risen up in the world. India also is prepping up to introduce two COVID vaccines and reached it’s human trials stage recently. A third phase of human trials will be performed by the Oxford University-AstraZeneca and Bharat Biotech which is being produced by Pune based Serum Institute of India.

The two Indian coronavirus vaccine competitors Bharat Biotech’s COVAXIN and Zydus Cadila’s inoculation ZyCoV-D are right now planning to do human clinical trials in six urban cities and soon to another six that includes 12 hospitals.

Zydus Cadila’s ZyCoV-D candidate is presently restricted for study only at Ahmedabad research centre. The trials will soon be scaled up in other cities too. COVAXIN is being experimented for safety study in Hyderabad, Patna, Rohtak, Delhi and Kancheepuram. It will be soon expanded to multiple cities that include Nagpur, Bhubaneswar, Belgaum, Gorakhpur, Kanpur, Visakhapatnam and Goa.

The recent reports state that on Friday a 30 year old volunteer became the first person from Delhi to receive 0.5ml intramuscular injection of Covaxin at All India institute of medical sciences (AIIMS).
Dr Sanjay Rai, principal investigator at AIIMS Delhi said that the person was healthy and hasn’t shown any marked adverse effects after administering the vaccine candidate for the first two hours and would re-examine after a couple of days.